Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749766 | 1.00 | TSHR (0.43) | TSHRALDH1A1CYP3A4RECQLHSD17B10 | |
| SCHEMBL29987444 | 0.98 | TSHR (0.42) | TSHRALDH1A1CYP3A4RECQLHSD17B10 | |
| SCHEMBL28602689 | 0.87 | TSHR (0.36) | TSHRALDH1A1CYP3A4RECQLSMN1; SMN2 | |
| SCHEMBL29390182 | 0.85 | ALDH1A1 (0.49) | TSHRALDH1A1CYP3A4RECQLHSD17B10 | |
| SCHEMBL381803 | 0.85 | ALDH1A1 (0.49) | TSHRALDH1A1CYP3A4RECQLHSD17B10 | |
| SCHEMBL3360541 | 0.80 | ALDH1A1 (0.46) | TSHRALDH1A1CYP3A4RECQLHSD17B10 | |
| SCHEMBL12489778 | 0.80 | TSHR (0.44) | TSHRALDH1A1CYP3A4MAPTGPR35 | |
| SCHEMBL32681751 | 0.78 | TSHR (0.42) | TSHRALDH1A1CYP3A4MAPTGPR35 | |
| SCHEMBL21684665 | 0.77 | ALDH1A1 (0.44) | TSHRALDH1A1CYP3A4RECQLMAPT | |
| SCHEMBL28980019 | 0.77 | PDE7A (0.41) | TSHRALDH1A1CYP3A4MAPTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069651-A | Continuous synthesis method of 2-chloro-4-amino-5-methylpyridine | 福建桦智工程技术有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-115340492-A | Preparation method of 2-hydroxy-4-amino-5-methylpyridine | 武汉海特生物创新医药研究有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-103193704-A | 2-hydroxy-4-amino-5-methylpyridine heterocyclic compound | SICHUAN BERARE BIOLOG MEDICAL CO LTD | 2013-07-10 | — | — | CN | claimed |
| CN-117069651-A | Continuous synthesis method of 2-chloro-4-amino-5-methylpyridine | 福建桦智工程技术有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-115340492-A | Preparation method of 2-hydroxy-4-amino-5-methylpyridine | 武汉海特生物创新医药研究有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-2799434-B1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | VERTEX PHARMA (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | disclosed |
| EP-2799434-A1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | Vertex Pharmaceuticals Incorporated (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| CN-103193704-A | 2-hydroxy-4-amino-5-methylpyridine heterocyclic compound | SICHUAN BERARE BIOLOG MEDICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-8431713-B2 | 2-aminopyridine derivatives as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2008091770-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171450-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | TSHR 1822/4885ALDH1A1 2442/4885CYP3A4 1438/4885 |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | TSHR 3256/4885ALDH1A1 820/4885CYP3A4 2492/4885 |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | TSHR 1261/4885ALDH1A1 714/4885CYP3A4 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.